Methods for therapeutic trials in COPD: lessons from the TORCH trial

The TORCH (Towards a Revolution in COPD Health) trial has highlighted some important issues in the design and analysis of long term trials in chronic obstructive pulmonary disease. These include collection of off-treatment exacerbation data, analysis of exacerbation rates and the effect of inclusion of patients receiving inhaled corticosteroids (ICS) prior to randomisation. When effective medications are available to patients who withdraw, inclusion of off-treatment data can mask important treatment effects on exacerbation rates. Analysis of on-treatment data avoids this bias but it needs to be combined with careful analysis of withdrawal patterns across treatments. The negative binomial model is currently the best approach to statistical analysis of exacerbation rates, while analysis of time to exacerbation can supplement this approach. In the TORCH trial, exacerbation rates were higher among patients with previous use of ICS compared to those with no prior use on all study treatments. Retrospective subgroup analysis suggests ICS reduced exacerbation rates compared with placebo, regardless of prior use of ICS before entry to the study. Factorial analysis provides an alternative analysis for trials with combinations of treatments, but assumes no interaction between treatments, an assumption which cannot be verified by a significance test. No definitive conclusions can yet be drawn on whether ICS treatment has an effect on mortality.

[1]  M. Duerden.  Prevention of death in COPD. , 2007, The New England journal of medicine.

[2]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[3]  ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. , 1999, Statistics in medicine.

[4]  J A Anderson,et al.  Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited , 2008, European Respiratory Journal.

[5]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Journal of the American Podiatric Medical Association.

[6]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[7]  Robert J. Temple,et al.  Special study designs: early escape, enrichment, studies in non-responders , 1994 .

[8]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[9]  C. Jenkins,et al.  The TORCH (TOwards a Revolution in COPD Health) survival study protocol , 2004, European Respiratory Journal.

[10]  C. la Vecchia,et al.  Prevention of death in COPD. , 2007, The New England journal of medicine.

[11]  A. V. Peterson,et al.  On the regression analysis of multivariate failure time data , 1981 .

[12]  John Weiner,et al.  Letter to the Editor , 1992, SIGIR Forum.

[13]  D G Altman,et al.  Statistics notes: Absence of evidence is not evidence of absence , 1995 .

[14]  S. Ellenberg,et al.  Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific Cases , 2000, Annals of Internal Medicine.

[15]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[16]  P. Kardos.  Methodological issues in therapeutic trials of COPD , 2008, European Respiratory Journal.

[17]  R. Kay.  Some Fundamental Statistical Concepts in Clinical Trials and their Application in Herpes Zoster , 1995 .

[18]  R. Prentice,et al.  Commentary on Andersen and Gill's "Cox's Regression Model for Counting Processes: A Large Sample Study" , 1982 .

[19]  K. Rabe,et al.  Five good reasons to read (and cite) the ERJ , 2008, European Respiratory Journal.

[20]  S. Spencer,et al.  Withdrawal from treatment as an outcome in the ISOLDE study of COPD. , 2003, Chest.

[21]  T. Seemungal,et al.  The INSPIRE Study: Influence of Prior Use and Discontinuation of Inhaled Corticosteroids , 2008 .

[22]  S. Pocock,et al.  Factorial trials in cardiology: pros and cons. , 1994, European heart journal.

[23]  R. Kay.  Statistical Principles for Clinical Trials , 1998, The Journal of international medical research.

[24]  S S Ellenberg,et al.  Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues , 2000, Annals of Internal Medicine.

[25]  J. Wittes,et al.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.

[26]  O. Keene,et al.  Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study , 2007, Pharmaceutical statistics.

[27]  S. Pocock,et al.  Clinical Trials: A Practical Approach , 1984 .